ABLYNX ANNOUNCES WARRANT EXERCISE GHENT, Belgium,

GHENT, Belgium, Oct. 21, 2013 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 25,531 common shares have been issued by the Company in exchange for 147,161.69 Euro as the result of the exercise of warrants by some employees and consultants of the Company.

As a result of this transaction, Ablynx now has 48,827,646 shares outstanding.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies ^® , a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and six Nanobodies at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com .

For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2345
e: ablynx@consilium-comms.com

pdf version of the press release: http://hugin.info/137912/R/1737065/582289.pdf